Skip to main content
. 2021 Sep 21;13:7299–7309. doi: 10.2147/CMAR.S318378

Figure 2.

Figure 2

Overexpressed SNHG22 correlates with poor prognosis in ovarian cancer. (A) Comparison of the expression level of SNHG22 in control, stage I–II (early stage) and stage III–IV (advanced stage) of EOC patients. (B) SNHG22 expression and survival predicted poor prognosis of OS in a cohort of 60 paired cases. (C) SNHG22 expression and survival predicted poor prognosis of PFS in the KM-plotter (http://kmplot.com/analysis/). (D) ROC curve analysis of the diagnostic value of SNHG22. (E) Gene set enrichment analysis of TCGA OV dataset showed enrichment of five pathways gene panels in the SNHG22 high expression group. (F) Analysis of the glycolic gene expression in SNHG22 knockdown or SNHG22 re-expression in A2780 cells. (G) SNHG22 co-expression heat map, TCGA (https://portal.gdc.cancer.gov/) OV, level 3 HTSeq-FPKM. *P < 0.05, **P < 0.01, ***P < 0.001.